Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines

被引：48

作者：

Alfagih, Iman M. ^{[1
]}

Aldosari, Basmah ^{[1
]}

AlQuadeib, Bushra ^{[1
]}

Almurshedi, Alanood ^{[1
]}

Alfagih, Mariyam M. ^{[2
]}

机构：

[1] King Saud Univ, Dept Pharmaceut, Coll Pharm, Riyadh 11671, Saudi Arabia

[2] Aalfaisal Univ, Dept Pharmaceut Sci, Coll Pharm, Riyadh 11533, Saudi Arabia

来源：

PHARMACEUTICS | 2021年 / 13卷 / 01期

关键词：

mRNA; adjuvant; vaccine; nanoparticles; nanodelivery systems; lipids; polymers;

D O I：

10.3390/pharmaceutics13010045

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Messenger RNA (mRNA)-based vaccines have shown promise against infectious diseases and several types of cancer in the last two decades. Their promise can be attributed to their safety profiles, high potency, and ability to be rapidly and affordably manufactured. Now, many RNA-based vaccines are being evaluated in clinical trials as prophylactic and therapeutic vaccines. However, until recently, their development has been limited by their instability and inefficient in vivo transfection. The nanodelivery system plays a dual function in RNA-based vaccination by acting as a carrier system and as an adjuvant. That is due to its similarity to microorganisms structurally and size-wise; the nanodelivery system can augment the response by the immune system via simulating the natural infection process. Nanodelivery systems allow non-invasive mucosal administration, targeted immune cell delivery, and controlled delivery, reducing the need for multiple administrations. They also allow co-encapsulating with immunostimulators to improve the overall adjuvant capacity. The aim of this review is to discuss the recent developments and applications of biodegradable nanodelivery systems that improve RNA-based vaccine delivery and enhance the immunological response against targeted diseases.

引用

页码：1 / 27

页数：27

共 155 条

[1] mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials [J].

A Feldman, Robert ;

Fuhr, Rainard ;

Smolenov, Igor ;

Ribeiro, Amilcar ;

Panther, Lori ;

Watson, Mike ;

Senn, Joseph J. ;

Smith, Mike ;

Almarsson, Orn ;

Pujar, Hari S. ;

Laska, Michael E. ;

Thompson, James ;

Zaks, Tal ;

Ciaramella, Giuseppe .

VACCINE, 2019, 37 (25) :3326-3334

[2] Dendrimers: synthesis, applications, and properties [J].

Abbasi, Elham ;

Aval, Sedigheh Fekri ;

Akbarzadeh, Abolfazl ;

Milani, Morteza ;

Nasrabadi, Hamid Tayefi ;

Joo, Sang Woo ;

Hanifehpour, Younes ;

Nejati-Koshki, Kazem ;

Pashaei-Asl, Roghiyeh .

NANOSCALE RESEARCH LETTERS, 2014, 9 :1-10

[3] PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy [J].

Abedi-Gaballu, Fereydoon ;

Dehghan, Gholamreza ;

Ghaffari, Maryam ;

Yekta, Reza ;

Abbaspour-Ravasjani, Soheil ;

Baradaran, Behzad ;

Dolatabadi, Jafar Ezzati Nazhad ;

Hamblin, Michael R. .

APPLIED MATERIALS TODAY, 2018, 12 :177-190

[4] Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis [J].

Adams, D. ;

Gonzalez-Duarte, A. ;

O'Riordan, W. D. ;

Yang, C. -C. ;

Ueda, M. ;

Kristen, A. V. ;

Tournev, I. ;

Schmidt, H. H. ;

Coelho, T. ;

Berk, J. L. ;

Lin, K. -P. ;

Vita, G. ;

Attarian, S. ;

Plante-Bordeneuve, V. ;

Mezei, M. M. ;

Campistol, J. M. ;

Buades, J. ;

Brannagan, T. H., III ;

Kim, B. J. ;

Oh, J. ;

Parman, Y. ;

Sekijima, Y. ;

Hawkins, P. N. ;

Solomon, S. D. ;

Polydefkis, M. ;

Dyck, P. J. ;

Gandhi, P. J. ;

Goyal, S. ;

Chen, J. ;

Strahs, A. L. ;

Nochur, S. V. ;

Sweetser, M. T. ;

Garg, P. P. ;

Vaishnaw, A. K. ;

Gollob, J. A. ;

Suhr, O. B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :11-21

[5] Noncytopathic Sindbis virus RNA vectors for heterologous gene expression [J].

Agapov, EV ;

Frolov, I ;

Lindenbach, BD ;

Pragai, BM ;

Schlesinger, S ;

Rice, CM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) :12989-12994

[6] Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial [J].

Alberer, Martin ;

Gnad-Vogt, Ulrike ;

Hong, Henoch Sangjoon ;

Mehr, Keyvan Tadjalli ;

Backert, Linus ;

Finak, Greg ;

Gottardo, Raphael ;

Bica, Mihai Alexandru ;

Garofano, Aurelio ;

Koch, Sven Dominik ;

Fotin-Mleczek, Mariola ;

Hoerr, Ingmar ;

Clemens, Ralf ;

von Sonnenburg, Frank .

LANCET, 2017, 390 (10101) :1511-1520

[7] Plant virus nanoparticles: Novel and robust nanocarriers for drug delivery and imaging [J].

Alemzadeh, Effat ;

Dehshahri, Ali ;

Izadpanah, Keramatolah ;

Ahmadi, Fatemeh .

COLLOIDS AND SURFACES B-BIOINTERFACES, 2018, 167 :20-27

[8] Poloxamers, poloxamines and polymeric micelles: Definition, structure and therapeutic applications in cancer [J].

Almeida, Mauro ;

Magalhes, Mariana ;

Veiga, Francisco ;

Figueiras, Ana .

JOURNAL OF POLYMER RESEARCH, 2017, 25 (01)

[9] Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery [J].

Anderson, DG ;

Lynn, DM ;

Langer, R .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (27) :3153-3158

[10] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults [J].

Anderson, E. J. ;

Rouphael, N. G. ;

Widge, A. T. ;

Jackson, L. A. ;

Roberts, P. C. ;

Makhene, M. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. B. ;

Flach, B. ;

Lin, B. C. ;

Doria-Rose, N. A. ;

O'Dell, S. ;

Schmidt, S. D. ;

Corbett, K. S. ;

Swanson, P. A., II ;

Padilla, M. ;

Neuzil, K. M. ;

Bennett, H. ;

Leav, B. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Edara, V. V. ;

Floyd, K. ;

Suthar, M. S. ;

Martinez, D. R. ;

Baric, R. ;

Buchanan, W. ;

Luke, C. J. ;

Phadke, V. K. ;

Rostad, C. A. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2427-2438

← 1 2 3 4 5 6 7 8 9 10 →